Bladder cancer treatment may lower risk for Alzheimer’s and related dementias
Jun 12, 2023
A greater effect was seen for patients aged 70 years and older at time of bacillus Calmette-Guerin vaccination.
Hearing intervention may have effect on cognitive change
Jul 20, 2023
No effect was seen in the total cohort composed of two populations, but sensitivity analysis revealed an effect of intervention in the cohort at higher risk for cognitive decline.
Study identifies factors that predict driving cessation in seniors
May 22, 2024
Older age, female sex and progression to symptomatic Alzheimer’s disease were associated with driving cessation.
Excess Alzheimer’s, related dementia-linked mortality increased during COVID-19
Jul 19, 2023
Among nursing home/long-term care residents, pandemic-era ADRD-related excess deaths decreased from 34,259 in year 1 to 22,050 in year 2, but excess deaths at home remained high (34,487 and 28,804, respectively).
Sleep-disordered breathing linked to medial temporal lobe atrophy in seniors
Jun 02, 2023
Higher sleep apnea severity was related to lower medial temporal lobe subregion volumes in amyloid-positive, but not amyloid-negative, individuals.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Financial altruism may indicate cognitive decline in seniors
Jun 22, 2022
“Trouble handling money is thought to be one of the early signs of Alzheimer’s disease, and this finding supports that notion.”
Retinal layer thickness linked to cognitive decline in older adults
May 27, 2022
Thinner baseline total macular retinal nerve fiber layer thickness was associated with a larger decline in cognitive function test scores during follow-up.
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.